Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A U.S. multi-centre post approval registry to analyse the CRBSI rate in patients with the NexSite HD Catheter for long term vascular access for hemodialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

NCT06714864

Catheter-Related Infections

RECRUITING PHASE4

Anticipative Diagnosis of Central Venous Catheter Related Bloodstream Infections

NCT01481038

Bloodstream Infection Due to Central Venous Catheter

COMPLETED

Developing and Maintaining a Central Venous Catheter Registry

NCT01165411

Infection

COMPLETED

Investigational Study With the BD PosiFlush™ SafeScrub on NADs

NCT06604026

CRBSI - Catheter Related Bloodstream Infection

RECRUITING NA

The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain

NCT02746419

Autosomal Dominant Polycystic Kidney Disease

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.

The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.

Secondary endpoints for the study are

* Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.
* Healing of catheter exit site
* Tunnel Infections
* Exit site infections
* Early non-infectious complications associated with CVCs
* Late non-infectious complications associated with Central Venous Catheters

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NexSite HD Patients

NexSite HD patient catheter device placement

Group Type EXPERIMENTAL

NexSite HD Patients

Intervention Type DEVICE

Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NexSite HD Patients

Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient shall be 18 - 80 years old.
2. The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
3. The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
4. The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
5. The patient receives the catheter via the internal jugular or subclavian vein.
6. All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.

Exclusion Criteria

1. The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
2. The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
3. The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
4. The patient is known or suspected to have allergies to the materials used in the construction of the device.
5. The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
6. The patient has received radiation treatment at the proposed catheter placement site.
7. The patient has severe chronic obstructive lung disease.
8. The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
9. The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device \[IUD\], birth control pills, or spermicidal gel with diaphragm or condom)
10. The patient has another indwelling catheter.
11. The patient has non-healing diabetic foot ulcers.
12. The patient did not give informed consent.
13. The patient would be unavailable for follow-up.
14. The patient is a permanent nursing home resident.
15. The proposed access site is not the internal jugular or subclavian vein.
16. The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
17. Any other condition that the Investigator believes should exclude the patient from the study.
18. The patient does not have English or Spanish as their first language.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No